ClinicalTrials.Veeva

Menu

A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients

NYU Langone Health logo

NYU Langone Health

Status

Completed

Conditions

Smoking Cessation

Treatments

Other: Treatment As Usual (TAU)
Drug: Nicotine Replacement Therapies
Behavioral: Text Message Intervention (TMI)

Study type

Interventional

Funder types

Other

Identifiers

NCT02665208
14-01654

Details and patient eligibility

About

The primary purpose of this study is to understand the feasibility of a text messaging intervention developed by the National Cancer Institute, known as Smokefreetxt, to improve smoking cessation among opiate and/or alcohol dependent participants discharged from an inpatient detoxification unit and enrolled in an office-based buprenorphine program patients (OBBP). Participants will be randomized to 1) treatment as usual (TAU) comprised of informational pamphlets and information for a 1800 quit line; and a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg) #10, for 28 days which is offered routinely to all inpatients at Bellevue at the time of discharge) versus the SmokeFreeTXT intervention plus prescriptions for NRT.

Enrollment

203 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • self-described every or some day smoker
  • diagnosed with opiate dependence and/or alcohol dependence (DSM-IV) per Physician medical records (MISYS)
  • Fluency in English and able to provide a written informed consent
  • Currently owning a mobile phone with a working phone number
  • Expected to reside in the New York City area for the next 12 months
  • Understands and able to respond to the intervention text message

Exclusion criteria

  • inability to read or understand English
  • currently using nicotine replacement therapies (patch, gum, e-cigarettes), pharmacotherapy for smoking cessation such as bupropion (zyban, wellbutrin), varenicline (Chantix).
  • suicidal or homicidal ideations
  • any ongoing psychotic disorder, life-threatening medical or psychiatric condition
  • leaves the inpatient detoxification unit prior to completing study enrollment
  • is pregnant, nursing or planning to conceive within the duration of the study period

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

203 participants in 3 patient groups

Treatment As Usual (TAU)
Active Comparator group
Description:
Participants will receive informational pamphlets and information for a 1800 quit line, and a prescription for a nicotine replacement therapy (NRT) for 7 Days
Treatment:
Other: Treatment As Usual (TAU)
Nicotine Replacement Therapies
Active Comparator group
Description:
Participants will receive a prescription for a nicotine replacement therapy (NRT) for 7 Days.
Treatment:
Drug: Nicotine Replacement Therapies
Text Message Intervention
Active Comparator group
Description:
Participants will receive up to 5 messages a day with message content informed by principles of cognitive behavioral therapy using software developed and maintained by the National Cancer Institute.
Treatment:
Behavioral: Text Message Intervention (TMI)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems